Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00166166 · ClinicalTrials.gov registry record · Phase 2
Endothelial Hyperpolarization in Humans
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT00166166: Clinical Trial Phase 2 study, sponsored by Emory University.
NCT00166166 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 174 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00166166, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
The purpose of this study is to elucidate the role Endothelium-Derived Hyperpolarizing Factor (EDHF) plays in dilating blood vessels and whether it differs between healthy people and those with high cholesterol. A second purpose of the study is to determine the identity of EDHF.
Primary Outcome
Simultaneous forearm blood flow (FBF) measurements were obtained in both arms using a dual-channel venous occlusion strain gauge plethysmograph at rest and after administration of tetraethylammonium (TEA). Flow measurements were recorded for approximately 7 seconds, every 15 seconds up to eight times and a mean FBF value was computed. Percent change is the difference from baseline FBF and after TEA administration.
Interventions
- DRUG Acetylcholine
- DRUG Sodium nitroprusside
- DRUG Bradykinin
- DRUG Tetraethylammonium (TEA)
- DRUG L-NG-monomethyl Arginine (L-NMMA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2002-07 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Why NCT00166166 stopped before completion
NCT00166166 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher).
The record links to 0 conditions, and to 5 interventions - of which Acetylcholine is the first listed.
NCT00166166 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00166166 about?
NCT00166166 is a clinical study titled "Endothelial Hyperpolarization in Humans". The purpose of this study is to elucidate the role Endothelium-Derived Hyperpolarizing Factor (EDHF) plays in dilating blood vessels and whether it differs between healthy people and those with high cholesterol. A second purpose of the study is to determine the identity of EDHF.
What is the current status of trial NCT00166166?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2002-07. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00166166?
The interventions under investigation include: Acetylcholine (DRUG), Sodium nitroprusside (DRUG), Bradykinin (DRUG), Tetraethylammonium (TEA) (DRUG), L-NG-monomethyl Arginine (L-NMMA) (DRUG).
Who is sponsoring clinical trial NCT00166166?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00166166's enrollment target sits among peer trials
174 396th of 2000 higher than 1,604 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia